Author:
Meyers Tammy,Krogstad Paul
Subject
Virology,Infectious Diseases,Immunology,Epidemiology
Reference9 articles.
1. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial;Turkova;Lancet HIV,2022
2. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach,2021
3. Global AIDS Update 2021. Confronting inequalities lessons for pandemic responses from 40 years of AIDS,2021
4. Update of recommendations on first- and second-line antiretroviral regimens,2019
5. Dolutegravir as first- or second-line treatment for HIV-1 infection in children;Turkova;N Engl J Med,2021